Ames National Corp’s AbbVie ABBV Stock Holding History

Ames National Corp’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$311K	Hold	1,465	–	–	0.19%	55
2025 Q4	$335K	Hold	1,465	–	–	0.2%	58
2025 Q3	$339K	Hold	1,465	–	–	0.2%	59
2025 Q2	$272K	Buy	+1,465	New	+$272K	0.18%	60
2025 Q1	–	Sell	-1,465	Closed	-$260K	–	63
2024 Q4	$260K	Buy	+1,465	New	+$269K	0.18%	63

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ames National Corp's ABBV Position: Q1 2026 in Review

Ames National Corp held its AbbVie (ABBV) position steady in Q1 2026 at 1,465 shares worth $311K. The position accounts for 0.19% of the portfolio, ranked #55.

Ames National Corp first reported a position in ABBV in Q4 2024 and has held it in 5 quarters since. The position peaked at $339K in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Ames National Corp held 1,465 shares of AbbVie worth $311K as of Q1 2026.
Ames National Corp left its AbbVie share count unchanged in Q1 2026.
AbbVie made up 0.19% of Ames National Corp's portfolio in Q1 2026, its #55 holding.
Ames National Corp first reported a position in AbbVie in Q4 2024 and has held it in 5 quarters since.
Ames National Corp's AbbVie position peaked at $339K in Q3 2025.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Ames National Corp's 13F filing for Q1 2026, filed 12 May 2026.